Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company developing a new class of small molecule precision cancer therapies targeting critical intracellular dependencies across various cancer types. Their lead programs include a first-in-class DHX9 inhibitor and a potentially best-in-class KIF18A inhibitor, designed to address high unmet needs in specific cancer indications. The company leverages expertise in RNA-modifying proteins and systematic mapping for drug discovery.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $75M
Date: 23-Jan-2024
Investors: Mirae Asset Capital Life Science, Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb, Johnson & Johnson Innovation – JJDC, Inc., The Column Group, Atlas Venture, Droia Ventures, GV, EcoR1 Capital, AbbVie Ventures, The Mark Foundation for Cancer Research, Timefolio Capital
Markets: Biopharmaceutical, Oncology, Cancer Therapeutics, Biotechnology, Drug Discovery, Other Pharmaceuticals and Biotechnology, Life Sciences
HQ: Lexington, Massachusetts, United States
Founded: 2017
Website: https://www.accenttx.com/
LinkedIn: https://www.linkedin.com/company/accenttherapeutics/
Twitter: https://twitter.com/accent_tx
Crunchbase: https://www.crunchbase.com/organization/accent-therapeutics
Leave a Comment
Comments
No comments yet.